FDA reports approval of Mylan’s ‘first generic’ version of Advair

The FDA reported the approval of Mylan’s (MYL) Wixela Inhub, the “first generic” version of Advair, which is marketed by GlaxoSmithKline (GSK). The approval date for Wixela Inhub is January 30, according to a post to the FDA website that states: “‘First generics’ are just what they sound like-the first approval by FDA which permits a manufacturer to market a generic drug product in the United States. FDA considers first generics to be important to public health, and prioritizes review of these submissions
https://thefly.com/landingPageNews.php?id=2856215